Results 61 to 70 of about 3,549 (185)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer

Cancer Reports, 2023
Background Pegfilgrastim is recommended in docetaxel plus ramucirumab (DTX + RAM) therapy for recurrent nonsmall cell lung cancer (NSCLC) because of the associated frequency of febrile neutropenia (FN).
Kosuke Hamai, Shinya Miyaka, Shinpei Tada, Suguru Fujita, Tetsu Hirakawa, Mirai Matsumura, Sayaka Ueno, Takuya Tanimoto, Nobuhisa Ishikawa   +8 more
doaj   +1 more source

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Cancer Science, Volume 117, Issue 4, Page 929-942, April 2026.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki, Satoshi Tetsumoto, Toshie Niki, Yasuhiko Suga, Akio Osa, Toshiyuki Minami, Shohei Koyama, Yoshito Takeda, Nobuyuki Takakura, Atsushi Kumanogoh   +20 more
wiley   +1 more source

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)

Frontiers in Oncology, 2023
IntroductionPegylated granulocyte colony-stimulating factor (G-CSF) has been widely used for preventing febrile neutropenia in various types of cancer treatment. In the present study, we prospectively evaluated the safety and efficacy of pegfilgrastim as
Ga-Young Song, Je-Jung Lee, Joon Ho Moon, Dajung Kim, Min Kyoung Kim, Hyo Jung Kim, Yeung-Chul Mun, Won-Sik Lee, Young Rok Do, Jae Hoon Lee, Sung-Hoon Jung, Jin Seok Kim   +11 more
doaj   +1 more source

A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer

Cancer, Volume 132, Issue 6, 15 March 2026.
ABSTRACT Background A randomized phase II screening trial of gemcitabine, nab‐paclitaxel, and cisplatin with a medically supervised ketogenic diet (MSKD) versus usual diet (non‐MSKD) was conducted in patients with treatment‐naive metastatic pancreatic ductal adenocarcinoma (PDAC).
Gayle S. Jameson, Denise J. Roe, Erkut Borazanci, Diana L. Hanna, Caroline G. P. Roberts, Meredith S. Pelster, Richard C. Frank, Angela T. Alistar, Alan M. Miller, J. Erin Wiedmeier‐Nutor, Sandra D. Algaze, Alison R. Zoller, Sarah J. Hallberg, Betsy C. Wertheim, Keehoon Lee, Derek Cridebring, Joshua D. Rabinowitz, Stephen Gately, Jennifer Keppler, Sunil Sharma, Daniel D. Von Hoff, Drew W. Rasco   +21 more
wiley   +1 more source

Society for Maternal‐Fetal Medicine Consult Series #76: Cancer in pregnancy

Pregnancy, Volume 2, Issue 2, March 2026.
Abstract Approximately one in 1000 pregnancies is complicated by the diagnosis of cancer each year, and the incidence of cancer among reproductive‐age individuals is increasing. Management of a pregnant person with cancer can be complex and warrants a multidisciplinary approach to care.
Society for Maternal‐Fetal Medicine (SMFM), Moti Gulersen, Clarissa Bonanno, Justin S. Brandt, Stephanie Pierce, Elyce H. Cardonick, SMFM Publications Committee   +6 more
wiley   +1 more source

Enhancing Severe Neutropenia Prediction: PKPD‐Informed Labeling for Machine Learning Models Trained on Real‐World Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 427-436, February 2026.
Accurately labeling outcomes in real‐world data for machine learning is challenging due to data sparsity and imbalances. This study developed and evaluated a pharmacokinetic–pharmacodynamic (PKPD)‐informed labeling strategy to enhance the risk prediction of docetaxel‐induced neutropenia.
Conor J O’Hanlon, Jonas Denck, Elif Ozkirimli, Stefanie Bendels, Candice Jamois, Clarisse Chavanne, Dirk Fey, Kimmo Porkka, Oscar Brück, Ken Wang   +9 more
wiley   +1 more source

Use of Filgrastim among Febrile Inpatients who Received Outpatient Filgrastim or Pegfilgrastim

, 2006
Purpose To characterize the inpatient use of filgrastim in cancer patients hospitalized for management of post-chemotherapy fever after receiving either outpatient filgrastim or pegfilgrastim.
A. Scott Mathis, Elena Beyzarov, Indu Lew, Robert T. Adamson   +3 more
core   +1 more source

Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration‐Resistant Prostate Cancer

The Prostate, Volume 86, Issue 3, Page 297-306, February 15, 2026.
ABSTRACT Background Cabazitaxel is a taxane agent associated with fewer symptomatic adverse events than docetaxel in treating castration‐resistant prostate cancer (CRPC), yet it is typically reserved for post‐docetaxel failure. This study assessed whether early switching from docetaxel to cabazitaxel could improve clinical outcomes.
Taketo Kawai, Kazuki Maki, Satoru Taguchi, Yoichi Fujii, Takehiro Tanaka, Jimpei Miyakawa, Jun Kamei, Shigenori Kakutani, Aya Niimi, Daisuke Yamada, Yuta Yamada, Tappei Takada, Tohru Nakagawa, Haruki Kume   +13 more
wiley   +1 more source

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

European Journal of Haematology, Volume 116, Issue 2, Page 174-184, February 2026.
ABSTRACT BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged ...
Marco Picardi, Annamaria Vincenzi, Claudia Giordano, Novella Pugliese, Alessia Scarpa, Assunta Lombardi, Elena Vigliar, Giancarlo Troncone, Rosaria Cappiello, Massimo Mascolo, Giovanni Esposito, Maria Prastaro, Ciro Santoro, Roberta Esposito, Carlo Gabriele Tocchetti, Ciro Mainolfi, Rosa Fonti, Silvana Del Vecchio, Fabio Trastulli, Mario Annunziata, Rossella Iula, Catello Califano, Marianna Carchia, Marcello Persico, Alessia Salemme, Emanuele Nicolai, Andrea Soricelli, Marco Salvatore, Fabrizio Pane   +28 more
wiley   +1 more source

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

, 2003
BACKGROUND: We evaluated the efficacy of a single fixed 6 mg dose of pegfilgrastim (a pegylated version of filgrastim) per cycle of chemotherapy, compared with daily administration of filgrastim, in the provision of neutrophil support.
Clemens, Michael, R.I. Lalisang, Lalisang, R I, S. Siena, H. Samonigg, Piccart-Gebhart, Martine, A. Galid, M.D. Green, Green, M D, V. Zani, Galid, A, Guillem, V, Zani, V, Koelbl, H, M.R. Clemens, International Pegfilgrastim 749 Study Group, V. Guillem, Renwick, Jennifer, J. Baselga, Liang, B C, Gascon, P, H. Koelbl, J. Renwick, B.C. Liang, Siena, S, M.J. Piccart, Baselga, J, Samonigg, H, P. Gascon   +28 more
core   +1 more source